Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Gorlin Syndrome

Interventions

DRUG: Patidegib Topical Gel
DRUG: Patidegib Topical Gel with no active patidegib

Sponsor

Sol-Gel Technologies, Ltd.